239 related articles for article (PubMed ID: 25534417)
1. The c-MET/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP/ABCG2 expression.
Jung KA; Choi BH; Kwak MK
Mol Pharmacol; 2015; 87(3):465-76. PubMed ID: 25534417
[TBL] [Abstract][Full Text] [Related]
2. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling.
Hu C; Li H; Li J; Zhu Z; Yin S; Hao X; Yao M; Zheng S; Gu J
Carcinogenesis; 2008 Dec; 29(12):2289-97. PubMed ID: 18820285
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing.
Choi BH; Ryoo IG; Kang HC; Kwak MK
PLoS One; 2014; 9(9):e107158. PubMed ID: 25226504
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer resistant protein (BCRP) is a molecular determinant of the outcome of photodynamic therapy (PDT) for centrally located early lung cancer.
Usuda J; Tsunoda Y; Ichinose S; Ishizumi T; Ohtani K; Maehara S; Ono S; Tsutsui H; Ohira T; Okunaka T; Furukawa K; Sugimoto Y; Kato H; Ikeda N
Lung Cancer; 2010 Feb; 67(2):198-204. PubMed ID: 19477032
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
[TBL] [Abstract][Full Text] [Related]
8. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
[TBL] [Abstract][Full Text] [Related]
10. Strongly amphiphilic photosensitizers are not substrates of the cancer stem cell marker ABCG2 and provides specific and efficient light-triggered drug delivery of an EGFR-targeted cytotoxic drug.
Selbo PK; Weyergang A; Eng MS; Bostad M; Mælandsmo GM; Høgset A; Berg K
J Control Release; 2012 Apr; 159(2):197-203. PubMed ID: 22349185
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Lopez JP; Wang-Rodriguez J; Chang C; Chen JS; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1022-7. PubMed ID: 17938326
[TBL] [Abstract][Full Text] [Related]
12. Expression of BAF57 in ovarian cancer cells and drug sensitivity.
Yamaguchi T; Kurita T; Nishio K; Tsukada J; Hachisuga T; Morimoto Y; Iwai Y; Izumi H
Cancer Sci; 2015 Apr; 106(4):359-66. PubMed ID: 25611552
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
[TBL] [Abstract][Full Text] [Related]
14. Functional cyclic AMP response element in the breast cancer resistance protein (BCRP/ABCG2) promoter modulates epidermal growth factor receptor pathway- or androgen withdrawal-mediated BCRP/ABCG2 transcription in human cancer cells.
Xie Y; Nakanishi T; Natarajan K; Safren L; Hamburger AW; Hussain A; Ross DD
Biochim Biophys Acta; 2015 Mar; 1849(3):317-27. PubMed ID: 25615818
[TBL] [Abstract][Full Text] [Related]
15. Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line.
Rhee MS; Schneider E
Biochem Pharmacol; 2005 Jan; 69(1):123-32. PubMed ID: 15588721
[TBL] [Abstract][Full Text] [Related]
16. Guggulsterone and bexarotene induce secretion of exosome-associated breast cancer resistance protein and reduce doxorubicin resistance in MDA-MB-231 cells.
Kong JN; He Q; Wang G; Dasgupta S; Dinkins MB; Zhu G; Kim A; Spassieva S; Bieberich E
Int J Cancer; 2015 Oct; 137(7):1610-20. PubMed ID: 25833198
[TBL] [Abstract][Full Text] [Related]
17. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
[TBL] [Abstract][Full Text] [Related]
18. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Doyle L; Ross DD
Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]